TeraWulf (WULF) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants John Larkin - SVP & Director of Investor RelationsPaul Prager - CEO, Co-Founder & ChairmanPatrick Fleury - Chief Financial OfficerMike Grondahl - Head of Equities & Director of ResearchNazar Khan - Co-Founder, COO, CTO & Executive DirectorBrett Knoblauch - Managing DirectorStephen Glagola - Director - Equity ResearchMartin Toner - Managing Director - Institutional Research, Growth & InnovationBill Papanastasiou - Vice Presid ...

Financial Data and Key Metrics Changes - The first quarter GMV was $94.7 million, up 3% year over year, outperforming end markets that continue to contract [23] - Net revenue was $22.5 million, up 2%, with transaction revenue making up approximately 75% of total revenue [29] - Adjusted EBITDA loss was $1.7 million, compared to a loss of $1.8 million last year, with an adjusted EBITDA margin loss of 8%, flat year over year [32] Business Line Data and Key Metrics Changes - Consumer GMV grew mid-single digits, while trade GMV was flat; jewelry and fashion posted the strongest performance, both growing double digits [26] - On-platform average order value (AOV) was nearly $2,600, up 4%, while median order value was approximately $12.50, also up 4% [24] - Unique seller accounts decreased by 23% year over year to approximately 5,900, but listings grew 5% to over 1.8 million [20][28] Market Data and Key Metrics Changes - The company experienced a return to organic traffic growth in Q1, with over 70% of traffic coming from organic sources [12][25] - Conversion rates increased year over year for six consecutive quarters, with a 10% improvement in Q1 compared to Q1 2023 [19] - The company noted a significant drop in conversion from March to April, primarily driven by changes in the macroeconomic environment [41][50] Company Strategy and Development Direction - The company aims to maintain growth and expense discipline while capturing additional market share, focusing on product-led growth strategies [4][11] - The 2025 roadmap includes themes such as accelerating organic traffic growth, competitive pricing, funnel optimization, and elevating service levels [11] - The company is committed to managing costs carefully and delivering on key initiatives that position it for long-term success [35] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a tougher demand backdrop for luxury home discretionary spending due to evolving trade policies and macroeconomic effects [5] - The company expects continued listings growth throughout 2025 and anticipates churn to normalize in Q2 [28][34] - The guidance for Q2 includes GMV of $85 million to $92 million, reflecting a decrease of 7% to an increase of 1% [33][34] Other Important Information - The company ended the quarter with a strong cash position of $101 million, down $2.9 million sequentially, which includes share repurchases [33] - The company has repurchased approximately 6.9 million shares for a total of $33.4 million since launching its first share buyback in August 2023 [33] Q&A Session Summary Question: Organic traffic and conversion gains - Management noted that organic traffic had declined for over a year but was restored to growth in Q1, with conversion gains being stable despite a drop from March to April [40][42] Question: Churn normalization - Management confirmed that churn is expected to normalize in Q2 as the company has passed the changes in the subscription pricing plan [44][45] Question: Active buyers growth - The increase in active buyers is directly related to conversion changes, with management emphasizing the need to remain vigilant regarding macroeconomic conditions [50] Question: Market share gains - Management indicated that market share has grown for five consecutive quarters, measured against syndicated credit card data for online furniture and luxury furniture markets [54] Question: ML pricing models - The rollout of ML pricing models has seen high adoption for items priced below $9,000, while adoption for higher-priced items remains lower due to fewer data points [56][58]

Financial Data and Key Metrics Changes - Total client assets at the end of March were $171 billion, slightly down from the start of the year, with average AUM approximately 1% lower compared to the fourth quarter [6] - Revenue for the first quarter was $219.6 million, down about 5% from the fourth quarter due to lower average AUM and fewer days in the quarter, but year-over-year revenue was higher [21][22] - Adjusted earnings per diluted share with tax benefit was $1.36, marking the second highest quarterly EPS in company history and a record for any first quarter [9][30] - Adjusted EBITDA was $116 million with a margin of 53%, reflecting a 90 basis point expansion from the first quarter of the previous year [30] Business Line Data and Key Metrics Changes - Gross sales increased by 41% from the last quarter, reaching $9.3 billion, the highest level of quarterly gross sales in three years [6] - The ETF AUM increased to over $13 billion, a 28% increase during the quarter and up 67% year-over-year [8] - The Amundi acquisition resulted in a doubling of fixed income AUM as a percentage of total assets from 14% to 28% [11] Market Data and Key Metrics Changes - The company ended the quarter with $44 billion of AUM sourced from clients outside the U.S., representing 15% of total AUM, compared to less than 5% previously [12][24] - Pioneer Investments generated positive net long-term flows of $1.7 billion in the first quarter, which is not included in the company's numbers due to the transaction closing on April 1 [13][27] Company Strategy and Development Direction - The company is strategically investing in distribution channels, data, technology, marketing, and intermediary partnerships to enhance organic growth [10][19] - Plans for several ETF launches in 2025 are underway, with a focus on expanding the product lineup [9][19] - The company aims to maintain a long-term margin target of 49%, despite short-term integration costs from the Amundi acquisition [45] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the underlying activity around flows, viewing the two large redemptions as one-time events that should not distort organic growth progress [7] - The company is well-positioned for organic growth with a larger sales force and enhanced resources dedicated to distribution efforts [19][66] - Management anticipates a potential acquisition announcement in 2025, leveraging the improved balance sheet and cash position [58] Other Important Information - The company returned $39 million to shareholders during the first quarter and increased the quarterly dividend to $0.49 per share [22] - The net leverage ratio remained steady at 1.7 times, with cash on hand increasing to $176 million [22][31] Q&A Session Summary Question: Can you elaborate on the rollout of new products outside the U.S.? - Management indicated that they are working with Amundi to identify successful products for international markets, with launches expected in the latter half of 2025 [35][38] Question: How will margins evolve in the near term? - Management confirmed that while margins are currently at 53%, they expect a slight decline during integration efforts, but remain bullish on achieving long-term targets of 49% [42][45] Question: What is the state of the acquisition pipeline? - Management stated that the company is in a strong position to execute sizable transactions and is leaning towards larger scaled opportunities [56][58] Question: How are fixed income and solutions performing in volatile markets? - Management noted that the fixed income platform has expanded and performed well, with positive net flows observed in the first quarter [64][66] Question: Have there been any dissynergies from the Amundi acquisition? - Management reported no dissynergies from the Amundi acquisition, highlighting positive net flows from Pioneer Investments [72][74] Question: What investments are being made to enhance organic growth? - Management detailed significant investments in sales, marketing, and data technology to support organic growth, with success measured by growth in business [84][87] Question: How important are alternative investment products for future acquisitions? - Management acknowledged the importance of alternative investments and is evaluating various strategies to incorporate them into the platform [90][92] Question: What is the rationale behind the change in dividend policy? - Management explained that the change allows for more opportunistic increases while prioritizing capital for acquisitions and growth [96][98]

FTAI Infrastructure (FIP) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Alan Andreini - Head - Investor RelationsKenneth Nicholson - CEO & PresidentGiuliano Bologna - Managing DirectorKen Nicholson - Chief Executive OfficerBrian Mckenna - Director - Equity ResearchGregory Lewis - Managing Director Operator Good day, and welcome to the First Quarter twenty twenty five FTAI Infrastructure Earnings Conference Call. At this time, all participants are in a listen only mode. After the speake ...

Assured Guaranty (AGO) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Robert Tucker - Senior Managing Director of Investor Relations & Corporate CommunicationsDominic Frederico - President & CEORobert Bailenson - Chief Operating OfficerBenjamin Rosenblum - Chief Financial OfficerTommy McJoynt - Director - Equity Research Conference Call Participants Marissa Lobo - Analyst Operator Good morning, and welcome to the Assured Guaranty Limited First Quarter twenty twenty five Earnings Confere ...

Harrow (HROW) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Jamie Webb - Director of Communications & Investor RelationsMark Baum - Chief Executive Officer and Chairman of the BoardAndrew Boll - Chief Financial OfficerJeffrey Cohen - MD - Equity ResearchYi Chen - Managing Director, Equity ResearchMayank Mamtani - Senior Managing Director Conference Call Participants Thomas Flaten - Senior Research AnalystChase Knickerbocker - Senior Equity Research Analyst - Healthcare Operator Good mo ...

MBIA (MBI) Q1 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Greg Diamond - Managing Director of Investor & Media RelationsWilliam Fallon - Director & CEOJoseph Schachinger - EVP & CFOJohn Staley - Founding Partner Operator Welcome to the MBIA Inc. First Quarter twenty twenty five Financial Results Conference Call. I would now like to turn the call over to Greg Diamond, Managing Director of Investor and Media Relations at MBIA. Please go ahead, sir. Greg Diamond Thank you, Chelsea. Yes, we ...

Financial Data and Key Metrics Changes - The company reported total revenues of $197.1 million for Q1 2025, representing a year-over-year increase of 43% on an as-reported basis and 32% on an organic basis [8][28] - Adjusted non-GAAP EBITDA was $50.7 million, compared to $37.6 million in the prior year period, reflecting strong operational performance [32] - Adjusted non-GAAP EPS for the quarter was $1.7, up from $1.21 in the prior year period [32] Business Line Data and Key Metrics Changes - Revenues from the rare disease segment were $69 million, up 87% from the prior year, driven by strong performance of Cortrophin Gel, which generated $52.9 million in revenues, a 43% increase [29][30] - The generics segment reported revenues of $98.7 million, an increase of 41% year-over-year, attributed to new product launches and strong execution in the base business [14][30] - Revenues from the brands portfolio were $25.1 million, a slight decrease of 2% from the prior year [29] Market Data and Key Metrics Changes - The overall ACTH category grew 27% to approximately $684 million in 2024, indicating a favorable market environment for Cortrophin Gel [9] - The company expects Cortrophin Gel revenues to increase by 34% to 38% in 2025, projecting revenues of $265 million to $274 million [10][33] - The retina products, ILUVIEN and YUTIQ, generated revenues of $16.1 million in Q1, with performance impacted by market access challenges for Medicare patients [11][29] Company Strategy and Development Direction - The company is focused on expanding its rare disease business, particularly through Cortrophin Gel, and is investing in evidence generation and new product presentations to enhance market penetration [19][20] - A bespoke commercial approach is being implemented to address market access challenges, particularly for ILUVIEN and YUTIQ, with plans to enhance sales force capabilities [24][25] - The company is committed to maintaining a strong U.S. manufacturing footprint, with over 90% of revenues coming from domestically produced goods, positioning itself favorably in light of potential pharmaceutical tariffs [16][94] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory of Cortrophin Gel, citing a significant unmet medical need and a large addressable patient population [19][64] - The company anticipates a return to sequential revenue growth in the latter half of 2025, following a strong first quarter performance [34] - Management acknowledged challenges in the retina segment but highlighted positive trends in demand and a strengthened sales team as factors that will support future growth [13][53] Other Important Information - The company is preparing for an upcoming trial with CG Oncology regarding a royalty obligation dispute, with the jury trial set to commence on July 21, 2025 [36][38] - The company has a strong balance sheet with $149.8 million in unrestricted cash and a gross leverage ratio of 3.5 times [32] Q&A Session Summary Question: How much should the prefilled syringe help Cortrophin? - Management noted that early responses to the prefilled syringe have been positive, as it reduces one step in the administration process, and they expect to see traction as the year progresses [42][43] Question: What gives confidence in accelerating ILUVIEN and YUTIQ sales? - Confidence is based on several factors, including performance outside the U.S., improvements in sales force strength, and positive impacts from a bespoke commercial approach [51][52] Question: What are the payer dynamics for Cortrophin as the category returns to growth? - Management indicated that payers appreciate the competition brought to the category and that collaboration will continue to ensure patient access [82] Question: How is the acquisition of Alimera performing? - Management expressed confidence in the long-term opportunity for ILUVIEN and YUTIQ, highlighted by the recent buyout of a royalty obligation [84]

Embecta (EMBC) Q2 2025 Earnings Call May 09, 2025 08:00 AM ET Company Participants Devdatt Kurdikar - President & CEOJake Elguicze - Senior VP & CFOMarie Thibault - Managing DirectorAnthony Petrone - Managing Director Equity Research Conference Call Participants Kallum Titchmarsh - AnalystMichael Polark - Senior Equity Research Analyst Devdatt Kurdikar And long term success. Turning to some fiscal second quarter highlights. Second quarter revenue totaled $259,000,000 which exceeded our expectations of betwe ...

Financial Data and Key Metrics Changes - The company reported a 38% year-over-year revenue growth in Q1 2025, achieving $280 million in revenue guidance for the year [7][20] - Cash flow from operations reached a record $19.7 million in the first quarter [7] - The company aims to generate approximately $232 million in revenue over the remaining three quarters of 2025 [7] Business Line Data and Key Metrics Changes - Vevi revenue increased by 35% sequentially from $16 million in Q4 2024 to $21.5 million in Q1 2025, prior to the launch of the VIVI Access for All program [8][21] - iHizo's sales were impacted by destocking in Q1 2025, but unit sales more than doubled in April compared to the first quarter average, indicating a return to growth [16][22] - Triassence completed critical market access initiatives in Q1, leading to a doubling of accounts ordering the product since the beginning of the year [19] Market Data and Key Metrics Changes - The company noted seasonality in its business, with Q1 typically being the weakest revenue period [9] - The specially branded products faced challenges in gross to net estimates, affecting recognizable revenue [10] Company Strategy and Development Direction - The company is focused on achieving and potentially exceeding its 2025 revenue guidance through various product lines, including Vevi, iHizo, and Triassence [20][24] - The VIVI Access for All program is seen as a transformative initiative that could significantly impact revenue growth [12][14] - The company is not planning to exit the compounding business, emphasizing its importance in building commercial relationships and credibility [33][56] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting revenue guidance, citing strong momentum in new prescriptions and refill rates for Vevi [21][24] - The company acknowledged challenges in the first quarter but expects significant improvement in subsequent quarters [58][92] - Management is optimistic about the long-term potential of its products and the overall business model [92] Other Important Information - The company is actively engaged in discussions for debt refinancing, aiming for a positive outcome by late summer or early fall [86][87] - The impact of current tariff policies on gross margins is estimated to be negligible, around 50 basis points [67][69] Q&A Session Summary Question: Price increase initiatives for iEZO - Management indicated that there were no significant price increases for iEZO, and some prices were actually decreased to enhance accessibility [26][29] Question: Project Beagle initiatives - Project Beagle aims to transition CLARITY C patients to Vevi, which is expected to be financially beneficial [30][31] Question: Sequential changes in iHizo - Management confirmed that unit demand for iHizo is returning to growth mode after destocking in Q1 [36][40] Question: Triassence volume inflection - Management noted that new accounts are opening and using Triassence, with positive signs for future growth [42][44] Question: Impact of tariffs on products - Management stated that the impact of tariffs on gross margins is minimal, around 50 basis points [67][69] Question: Transition of compounding products to prescription - Management highlighted the hidden value in the compounding business and its role in building commercial relationships [53][55] Question: Revenue dynamics for iHizo - Management acknowledged the need for improvement in revenue and unit demand for iHizo, with expectations for growth in 2025 [75][76] Question: VIVI patient transition from CLARITY - Management confirmed that over 25,000 patients are being transitioned from CLARITY C to Vevi, with positive feedback from KOLs [77][80] Question: Debt refinancing outlook - Management expressed confidence in achieving favorable terms for debt refinancing by late summer or early fall [86][87]